Metabolic Disorder Diagnosis via Genetic Variant Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for type 2 diabetes and related metabolic disorders, such as those associated with metabolically obese normal weight (MONW) and lipodystrophy, lack effective therapeutic targets and risk markers, particularly for individuals with specific genetic loci variants like rs6712203 and rs12454712, which affect COBLL1, BCL2, and VPS4B expression in adipocytes and skeletal muscle.
Innovation Solution
Administering therapeutically effective amounts of agents that increase COBLL1 or BCL2 expression, inhibit apoptosis, or reduce VPS4B activity in adipocytes and adipocyte progenitors, using small molecules or gene editing systems like CRISPR-Cas to correct genomic variants, and employing adoptive cell transfer with genetically modified adipocyte progenitors to restore wild-type sequences.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current standard treatments are used for type 2 diabetes, then general glycemic control is achieved, but they lack effectiveness for specific genetic subgroups (MONW/MOH patients with rs6712203 and rs12454712 variants)
Solution Approach 1:
The patent applies local quality by developing treatment protocols specifically tailored to patients with particular genetic variants (rs6712203 in COBLL1 and rs12454712 in BCL2). Instead of uniform treatment, the invention identifies distinct patient subgroups based on their genetic profile and prescribes specific therapeutic agents (such as actin-stabilizing compounds for COBLL1 variants and apoptosis inhibitors for BCL2 variants) that target their unique pathological mechanisms, thereby improving treatment reliability for these specific genetic subgroups.
Solution Approach 2:
The patent implements dynamics by creating an adaptive treatment framework that can respond to different genetic profiles. The diagnostic system dynamically identifies patient genotype, and the treatment protocol dynamically adjusts based on this information - selecting from different therapeutic pathways (actin remodeling agents, apoptosis inhibition, lipid metabolism modulation) depending on which genetic variant is present, thus achieving both personalization and improved effectiveness.
2Loss of information
If genome-wide association studies identify multiple disease-associated loci, then comprehensive disease understanding is achieved, but the mechanisms converging to modulate disease susceptibility remain unclear
Solution Approach 1:
The patent extracts and focuses on specific key mechanisms from the complex web of GWAS-identified loci. Rather than attempting to address all hundreds of T2D loci simultaneously, the invention isolates and investigates particular pathways (actin cytoskeleton remodeling via COBLL1, apoptosis regulation via BCL2, lipid metabolism via VPS4B) that are directly actionable and can be targeted with specific therapeutic agents, thereby reducing mechanistic complexity to treatable components.
Solution Approach 2:
The patent introduces intermediary molecular pathways that connect genetic variants to disease phenotype. For example, it identifies actin cytoskeleton remodeling as an intermediary mechanism between COBLL1 genetic variants and adipocyte dysfunction, and apoptosis regulation as an intermediary between BCL2 variants and lipid-accumulating cell death. These intermediaries provide clear mechanistic links that can be targeted therapeutically.
3Adaptability or versatility
If therapeutic agents target multiple cell types and tissues, then pleiotropic effects are achieved, but the specific mechanisms in adipocytes and skeletal muscle remain undefined
Solution Approach 1:
The patent applies local quality by defining cell-type-specific mechanisms for genetic variant effects. It distinguishes how COBLL1 variants affect actin remodeling specifically in adipocytes versus how BCL2 variants affect apoptosis in skeletal muscle and adipose tissue. This cell-type-specific mechanistic understanding allows for precise therapeutic targeting - using actin-stabilizing compounds specifically for adipocyte actin defects and apoptosis inhibitors specifically for muscle and fat tissue protection.
4Reliability
If genetic variants affect COBLL1, BCL2, and VPS4B expression, then specific molecular targets are identified, but effective therapeutic agents and risk markers are still lacking
Solution Approach 1:
The patent introduces intermediary therapeutic mechanisms that translate genetic target identification into treatable pathways. For COBLL1 variants, it identifies actin cytoskeleton remodeling as the intermediary mechanism and selects actin-stabilizing compounds as therapeutic intermediaries. For BCL2 variants, it uses apoptosis inhibition as the intermediary mechanism with corresponding anti-apoptotic agents. For VPS4B variants, it employs lipid metabolism modulation as the intermediary with relevant metabolic agents, thereby bridging genetic targets to available therapeutics.
Data Source
AI summary
Most disease-associated genetic loci map to more than one disease or trait, suggesting they act through multiple cell types and tissues giving rise to complex disease phenotypes. This pervasive pleiotropy of human diseases presents a tremendous burden on identifying mediating mechanisms and therapeutic targets. Multiple metabolic risk haplotypes are associated with risk for metabolic diseases. However, whether a haplotype actually causes a disease and the mechanisms that cause the disease are unknown. Integration of phenotypic and transcriptional profiling in primary human cells allows for functional characterization of disease-associated genetic variants. Applicants have analyzed multiple risk haplotypes and determined the function of risk haplotypes involved in causation of specific metabolic phenotypes, such as type 2 diabetes and lipodystrophy. Methods of treatments are disclosed herein.